Mesa Laboratories (MLAB) Downgraded to “Strong Sell” at BidaskClub
BidaskClub downgraded shares of Mesa Laboratories (NASDAQ:MLAB) from a sell rating to a strong sell rating in a research report report published on Tuesday.
Other equities analysts have also issued research reports about the stock. ValuEngine upgraded shares of Mesa Laboratories from a hold rating to a buy rating in a research report on Wednesday, June 6th. TheStreet lowered shares of Mesa Laboratories from a b- rating to a c rating in a research report on Tuesday, August 21st. Finally, Zacks Investment Research upgraded shares of Mesa Laboratories from a hold rating to a buy rating and set a $248.00 price objective for the company in a research report on Wednesday, July 11th.
Shares of MLAB opened at $181.30 on Tuesday. The stock has a market capitalization of $733.47 million, a P/E ratio of 29.34 and a beta of 0.23. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.10 and a quick ratio of 1.55. Mesa Laboratories has a 52-week low of $122.35 and a 52-week high of $224.95.
The business also recently declared a quarterly dividend, which was paid on Monday, September 17th. Stockholders of record on Friday, August 31st were given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.35%. The ex-dividend date was Thursday, August 30th. Mesa Laboratories’s dividend payout ratio (DPR) is 10.36%.
In other news, Director David M. Kelly sold 700 shares of Mesa Laboratories stock in a transaction that occurred on Thursday, September 13th. The shares were sold at an average price of $190.01, for a total value of $133,007.00. Following the transaction, the director now owns 3,600 shares of the company’s stock, valued at $684,036. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO John Sakys sold 1,000 shares of the firm’s stock in a transaction on Wednesday, August 15th. The stock was sold at an average price of $203.50, for a total transaction of $203,500.00. Following the completion of the sale, the chief financial officer now owns 3,500 shares in the company, valued at approximately $712,250. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 4,400 shares of company stock worth $864,060. Insiders own 15.70% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Virtu Financial LLC bought a new position in shares of Mesa Laboratories during the second quarter valued at $248,000. Cambridge Investment Research Advisors Inc. bought a new stake in Mesa Laboratories during the 1st quarter worth about $255,000. Paloma Partners Management Co acquired a new position in shares of Mesa Laboratories during the 2nd quarter worth about $284,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Mesa Laboratories during the 2nd quarter worth about $298,000. Finally, Envestnet Asset Management Inc. grew its position in shares of Mesa Laboratories by 30.2% during the 1st quarter. Envestnet Asset Management Inc. now owns 2,051 shares of the medical instruments supplier’s stock worth $304,000 after buying an additional 476 shares during the period. Hedge funds and other institutional investors own 72.10% of the company’s stock.
About Mesa Laboratories
Mesa Laboratories, Inc designs, manufactures, and markets quality control instruments and disposable products. The company's Instruments segment offers data loggers, which are precision instruments used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air monitoring; and torque testing systems used for measure bottle cap tightness.
Further Reading: Technical Analysis of Stocks and What It Means
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.